Kaletra: Therapy With Double Protease Inhibitors

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

NCT00038519 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

NCT01153269 ·Status: COMPLETED

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

NCT00234910 ·Status: COMPLETED ·Phase: PHASE3

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

NCT01097655 ·Status: COMPLETED

Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use

NCT01379703 ·Status: COMPLETED

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

NCT00234975 ·Status: COMPLETED ·Phase: PHASE4

Kaletra-isentress Treatment Evaluation

NCT00700115 ·Status: COMPLETED ·Phase: PHASE4

Drug Use Investigation of Kaletra

NCT01076972 ·Status: COMPLETED

Surveillance of Kaletra in Korean Patients

NCT01083173 ·Status: COMPLETED

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

NCT00648999 ·Status: COMPLETED ·Phase: PHASE4

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

NCT01074931 ·Status: COMPLETED

Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra

NCT00176033 ·Status: COMPLETED

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778 ·Status: TERMINATED ·Phase: PHASE2

Kaletra Monotherapy in HIV/HCV Co-infected Subjects

NCT00508222 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients

NCT00234923 ·Status: COMPLETED ·Phase: PHASE3

Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC

NCT00865475 ·Status: COMPLETED ·Phase: PHASE4

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

NCT00234962 ·Status: TERMINATED ·Phase: PHASE4

BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

NCT00414284 ·Status: TERMINATED ·Phase: PHASE4

Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients

NCT00140751 ·Status: COMPLETED ·Phase: PHASE3

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

NCT00258557 ·Status: COMPLETED ·Phase: PHASE3

The Effect of Lopinavir/Ritonavir on Endothelial Function

NCT00076414 ·Status: COMPLETED ·Phase: PHASE1

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

NCT00038532 ·Status: COMPLETED ·Phase: PHASE2

Kaletra Sex/Gender Pharmacokinetics (PK) Study

NCT00148759 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)

NCT01103596 ·Status: COMPLETED

A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation

NCT04138199 ·Status: TERMINATED